Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Researchers Uncover Gene Involved In Type 1 Diabetes



The researchers recently discovered that in a mouse model of type 1 diabetes, RGS1 has an effect on T follicular helper cells that are necessary for B cell development and antibody production.

Share this!

April 14, 2016 | by Sarah Massey, M.Sc.

Type 1 diabetes is classified as an autoimmune disease in which the immune system mounts an attack against the body’s insulin-secreting cells. According to Dr. Stephan Kissler, Investigator in the Section on Immunobiology at Joslin Diabetes Center, and Assistant Professor of Medicine at Harvard Medical School, our understanding of the genetic basis of this autoimmune reaction, is severely lacking.

Dozens of genetic mutations have been implicated in type 1 diabetes, and research is ongoing to uncover each gene’s role in disease onset and progression. Kissler’s lab has focused on one of these genes – known as RGS1 – and his team have recently elucidated its role in promoting the autoimmune response present in type 1 diabetics.

Researchers know that T cells are responsible for invading the pancreas and damaging insulin-producing beta cells, and that B cells produce antibodies that are targeted towards the pancreatic cells. Kissler and his colleagues recently discovered that in a mouse model of type 1 diabetes, RGS1 has an effect on T follicular helper cells that are necessary for B cell development and antibody production.

“In a nutshell, what we found is that this gene has an effect on the frequency of these T follicular helper cells, which are important for the B cells and seem to be important for the disease,” said Kissler. Previous clinical studies have identified that patients with the disease have higher levels of T follicular helper cells circulating in the blood.

When Kissler and his team engineered mice to produce lower levels of RGS1 protein, they found that the progression of the disease was not impeded. According to the researchers, this result suggests that RGS1 may not be the best therapeutic target for diabetes.

“Inhibiting RGS1 didn't prevent autoimmune diabetes from happening, which is slightly disappointing but not surprising because any one of these genes in humans has a very small effect on risk,” said Kissler. Despite the disappointing result, Kissler’s group could still uncover a valuable target in one of the other genes they study, which are thought to be involved in type 1 diabetes and other autoimmune disorders.

In addition to its potential role in immune response, RGS1 is also thought to be involved in cell migration. Kissler points out that mutations of the gene have also been associated with other autoimmune disorders including multiple sclerosis.

Despite the finding that inhibiting RGS1 did not have an effect on the movement of T cells into the pancreas, the researcher did find that the gene manipulation was able to alter the way the cells move within the spleen and the lymph nodes. As these organs are important in facilitating the interaction between T follicular helper cells and B cells to encourage antibody production, this was a particularly crucial finding.

“The RGS1 gene is important to allow activated T cells to move into the regions with all the B cells, where they help the B cells get activated and produce antibodies,” said Kissler. “These are the T follicular helper cells. If you don't have any of these cells, the antibody production doesn't work anymore.”

“Overall, the T follicular helper cells are important for B cells, you have more of those T cells in people with type 1 diabetes, they seem to be very important for the disease, and we have a new explanation of why RGS1 has been implicated,” he said. The researchers plan to continue to test other genes to determine their effect on the progression of type 1 diabetes.

Keywords: Type 1 Diabetes, Autoimmune Disease, Genetic Mutation


Share this with your colleagues!

Nanoparticles Could Be Used To Treat Inflammatory Bowel Disease

April 12, 2016 - Researchers at the Institute for Biomedical Sciences at Georgia State University in the US, and Southwest University in China, have designed a novel nanoparticle capable of blocking expression of a glycoprotein that promotes intestinal inflammation.

AstraZeneca and Eli Lilly Pursue Late-Stage Clinical Trial For Alzheimer’s Drug

April 11, 2016 - Pharmaceutical powerhouses AstraZeneca and Eli Lilly have announced that they will be pushing their experimental Alzheimer’s candidate into a Phase III clinical trial.

FDA Approves Celltrion’s Remicade Biosimilar

April 11, 2016 - Celltrion’s Inflectra – a biosimilar to Janssen Biotech’s Remicade – is the second biosimilar to be approved by the US Food and Drug Administration (FDA).


The Surprising Link Between Off-Label Prescribing Practices And Adverse Drug Events


Copyright © 2016-2017 Honeycomb Worldwide Inc.